"Multiple Myeloma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Descriptor ID |
D009101
|
| MeSH Number(s) |
C04.557.595.500 C14.907.454.460 C15.378.147.780.650 C15.378.463.515.460 C20.683.515.845 C20.683.780.650
|
| Concept/Terms |
Multiple Myeloma- Multiple Myeloma
- Multiple Myelomas
- Myelomas, Multiple
- Myeloma, Multiple
- Myeloma, Plasma-Cell
- Myeloma, Plasma Cell
- Myelomas, Plasma-Cell
- Plasma-Cell Myeloma
- Plasma-Cell Myelomas
- Myelomatosis
- Myelomatoses
- Plasma Cell Myeloma
- Cell Myeloma, Plasma
- Cell Myelomas, Plasma
- Myelomas, Plasma Cell
- Plasma Cell Myelomas
- Kahler Disease
- Disease, Kahler
- Myeloma-Multiple
- Myeloma Multiple
- Myeloma-Multiples
|
Below are MeSH descriptors whose meaning is more general than "Multiple Myeloma".
Below are MeSH descriptors whose meaning is more specific than "Multiple Myeloma".
This graph shows the total number of publications written about "Multiple Myeloma" by people in this website by year, and whether "Multiple Myeloma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1998 | 3 | 0 | 3 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 5 | 0 | 5 |
| 2006 | 3 | 0 | 3 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 2 | 0 | 2 |
| 2010 | 2 | 0 | 2 |
| 2011 | 6 | 1 | 7 |
| 2012 | 4 | 0 | 4 |
| 2013 | 7 | 0 | 7 |
| 2014 | 4 | 0 | 4 |
| 2015 | 10 | 0 | 10 |
| 2016 | 7 | 0 | 7 |
| 2017 | 5 | 0 | 5 |
| 2018 | 8 | 0 | 8 |
| 2019 | 8 | 0 | 8 |
| 2020 | 12 | 0 | 12 |
| 2021 | 9 | 0 | 9 |
| 2022 | 7 | 0 | 7 |
| 2023 | 5 | 0 | 5 |
| 2024 | 5 | 0 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Multiple Myeloma" by people in Profiles.
-
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis. Blood. 2025 Jan 02; 145(1):75-84.
-
Trajectory, interactions, and predictors of higher symptom burden during induction therapy for multiple myeloma. J Patient Rep Outcomes. 2024 Dec 04; 8(1):141.
-
Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation. Blood Cancer J. 2024 10 31; 14(1):189.
-
Ophthalmoplegia Associated With Extramedullary Multiple Myeloma: Case Series From a Tertiary Cancer Center. J Neuroophthalmol. 2024 Dec 01; 44(4):533-539.
-
Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma With Deletion 17p. Transplant Cell Ther. 2025 Jan; 31(1):12.e1-12.e10.
-
The SAGA acetyltransferase module is required for the maintenance of MAF and MYC oncogenic gene expression programs in multiple myeloma. Genes Dev. 2024 Sep 19; 38(15-16):738-754.
-
Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience. Blood Adv. 2024 09 10; 8(17):4679-4688.
-
Features that characterize monoclonal light chain ("myeloma") cast nephropathy with immunofluorescence challenges and emphasis on electron microscopy. Ultrastruct Pathol. 2024 Sep 02; 48(5):422-437.
-
Early palliative care versus usual haematological care in multiple myeloma: retrospective cohort study. BMJ Support Palliat Care. 2024 Aug 19; 14(3):291-294.
-
Leukocyte immunoglobulin-like receptor B1 (LILRB1) protects human multiple myeloma cells from ferroptosis by maintaining cholesterol homeostasis. Nat Commun. 2024 Jul 09; 15(1):5767.